Shivani Srivastava, PhD
Associate Research ScientistDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Associate Research Scientist
Biography
Shivani Srivastava earned her Ph.D. in Biochemistry from the Institute of Medical Sciences, BHU, India, where her doctoral research focused on the molecular mechanisms of diabetes, with particular emphasis on pancreatic β-cell & intestinal adaptation, incretin hormones, and phytotherapeutic modulation of metabolic pathways. This work provided rigorous training in metabolic and endocrine biology and established a long-standing interest in understanding how cellular stress responses contribute to metabolic disease.
In March 2020, she moved to the United States to further expand her research training. She initially worked at The Ohio State University and later at UCLA, where she explored the cellular and molecular pathways connecting metabolic dysregulation to cardiovascular disease progression.
She then joined Yale University, where her research has focused on rare skeletal and metabolic disorders, including Hutchinson-Gilford progeria syndrome, ENPP1-associated obesity, hearing loss (co-first author, PMID: 40495691), and ossification of the posterior longitudinal ligament (OPLL) (PMID: 41251406). Using genetically engineered mouse models, in vitro approaches, and stem cell differentiation assays, her work examines how metabolic enzymes and disease-associated genetic variants regulate skeletal mineralization, adipose biology, and systemic metabolic homeostasis. These studies aim to uncover disease mechanisms and evaluate therapeutic potential.
By integrating disease-relevant preclinical models with mechanistic studies, her research seeks to bridge basic science and clinical translation in the fields of bone disease, metabolic diseases (including diabetes and obesity), and cardiovascular disease.
Last Updated on January 21, 2026.
Appointments
Cellular & Molecular Physiology
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Associate
- School of Medicine, Yale University, USA
- Postdoctoral Scholar
- David Geffen School of Medicine, UCLA, USA
- Postdoctoral Scholar
- Wexner Medical Center, OSU, USA
- PhD
- Institute of Medical Sciences, BHU, India
Research
Copy Link
Overview
Medical Research Interests
Bone Diseases; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Metabolic Diseases; Obesity
ORCID
0000-0001-8042-4476
Publications
Featured Publications
The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice.
Srivastava S*, Kato H*, von Kroge S*, Weise K, Stabach P, Lopez SG, O'Brien K, Lester ER, Kim H, Ishaq T, Dammen-Brower K, Schinke T, Kimura S, Miyahara J, Doi T, Oshima Y, Yarema KJ, Carpenter TO, Sabbagh Y, Tommasini SM, Ito N, Oheim R, Braddock DT. The prevalence of ENPP1 deficiency in humans with OPLL and the preclinical efficacy of ENPP1 enzyme therapy in OPLL mice. Journal of Bone and Mineral Research. 2025 PMID: 41251406, DOI: 10.1093/jbmr/zjaf168.Peer-Reviewed Original ResearchImprovements in hearing loss with bone-targeted enzyme replacement therapy are associated with corrected hypomineralization and osteocyte properties of auditory ossicles in Enpp1-deficient mice.
Ocokoljic A*, Srivastava S*, von Kroge S, Stabach PR, Busse B, Weise K, Oheim R, Rolvien T†, Braddock DT†. Improvements in hearing loss with bone-targeted enzyme replacement therapy are associated with corrected hypomineralization and osteocyte properties of auditory ossicles in Enpp1-deficient mice. Journal of Bone and Mineral Research. 2025;40(9):1077–1086. PMID: 40495691, DOI: 10.1093/jbmr/zjaf082.Peer-Reviewed Original ResearchExpression kinetics reveal the self-adaptive role of β cells during the progression of diabetes
Srivastava S, Pandey H, Tripathi Y. Expression kinetics reveal the self-adaptive role of β cells during the progression of diabetes. Biomedicine & Pharmacotherapy 2018, 106: 472-482. PMID: 29990835, DOI: 10.1016/j.biopha.2018.06.168.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdaptation, PhysiologicalAnimalsApoptosisApoptosis Regulatory ProteinsAutophagyAutophagy-Related ProteinsBiomarkersCell Cycle ProteinsCell HypoxiaCell ProliferationCellular MicroenvironmentDiabetes Mellitus, ExperimentalDisease ProgressionEnergy MetabolismGene Expression RegulationInflammation MediatorsInsulin-Secreting CellsKineticsMaleRatsConceptsB cellsLymphocytic infiltrationDays of injectionBiphasic patternB cell proliferationOnset of diabetesOvernight fasted ratsProgression of diabetesProgressive diabetesExpression of incretin receptorsInflammatory markersSTZ injectionSTZ administrationProtective markerBiphasic pattern of expressionIncretin receptorsIL-6Pattern of expressionBcl-2Fasted ratsGLP-1RBlood glucoseHIF-1aNF-kBDrug interventionIncretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis
Srivastava S, Shree P, Pandey H, Tripathi Y. Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis. Biomedicine & Pharmacotherapy 2017, 97: 330-338. PMID: 29091882, DOI: 10.1016/j.biopha.2017.10.071.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBinding energyDissociation constantIn silico molecular docking approachPTY-2Molecular docking approachIn silico molecular dockingReceptor agonistsPlasma levelsGIP-RDPPIV inhibitorsPlasma levels of GLP-1Pancreatic expressionDiabetic controlDocking approachGLP-1RLevels of GLP-1Molecular dockingH & E stainingHormone receptor agonistsHormone receptor signalingExpression of GLP-1RExpression of genesSTZ-induced diabetesLesser side effectsComparison to diabetic controlsGLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes
Srivastava S, Pandey H, Singh S, Tripathi Y. GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes. Advanced Pharmaceutical Bulletin 2019, 9: 325-330. PMID: 31380261, PMCID: PMC6664108, DOI: 10.15171/apb.2019.039.Peer-Reviewed Original ResearchCitationsConceptsSingle dose of streptozotocinGLP-1Insulin expressionHigh-fat dietCell apoptosisDecreased insulin expressionLevels of GLP-1Groups of diabetic ratsWeeks of high-fat dietDose of streptozotocinGLP-1 levelsIntestinal epithelial cellsB-cell damageIntestinal cell apoptosisIncretin hormone secretionDiabetic control groupDipeptidyl peptidase 4Onset of type 2 diabetesType 2 diabetesGLP-1 analoguesSingle doseDiabetes onsetT2D ratsHormone secretionDiabetic ratsAnti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets
Srivastava S, Pandey H, Singh S, Tripathi Y. Anti-oxidant, anti-apoptotic, anti-hypoxic and anti-inflammatory conditions induced by PTY-2 against STZ-induced stress in islets. BioScience Trends 2019, 13: 382-393. PMID: 31597821, DOI: 10.5582/bst.2019.01181.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsActive phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach
Srivastava S, Shree P, Tripathi Y. Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach. Journal Of Diabetes & Metabolic Disorders 2017, 16: 46. PMID: 29201861, PMCID: PMC5697100, DOI: 10.1186/s40200-017-0328-0.Peer-Reviewed Original ResearchCitationsConceptsOral glucose tolerance testDPP IV activityActive phytochemicalsDPP-IV inhibitionGLP-1Postprandial stateDiabetic modelDPP-IV inhibitory propertiesPueraria tuberosaIntestinal homogenatesLevels of GLP-1Water extractTolerance responseGLP-1 plasma concentrationsSecretion of GLP-1Basal insulin concentrationsGlucose tolerance testDPP-IVCharles Foster ratsComparison to diabetic controlsHPLC-MSControl ratsPotential phytochemicalsFasting bloodBasal insulinRevolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies
Srivastava S*, Tyagi A*, Pawar VA*, Khan NH*, Arora K, Verma C†, Kumar V†. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies. Immunotargets Ther 2024, 13: 413-433. PMID: 39219644, DOI: 10.2147/ITT.S474659.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCatalysis-Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass
Zimmerman K*, Liu X*, von Kroge S*, Stabach P, Lester ER, Chu EY, Srivastava S, Somerman MJ, Tommasini SM, Busse B, Schinke T, Carpenter TO, Oheim R, Braddock DT. Catalysis‐Independent ENPP1 Protein Signaling Regulates Mammalian Bone Mass. Journal Of Bone And Mineral Research 2022, 37: 1733-1749. PMID: 35773783, PMCID: PMC9709593, DOI: 10.1002/jbmr.4640.Peer-Reviewed Original ResearchA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNA
Academic Achievements & Community Involvement
Copy Link
Activities
activity Diabetology
2026 - PresentJournal ServiceGuest EditorDetailsShivani Srivastava, PhD, associate research scientist in the Department of Cellular and Molecular Physiology, has been named guest editor for the Diabetology special issue on “Bone Metabolism and Skeletal Health in Diabetes.” The issue will showcase advances in basic, translational, and clinical research focused on diabetes-related bone health complications. Srivastava recently served as a topic editor for the Frontiers in Aging collection titled “Unraveling the Complexities of Premature Aging: Mechanisms and Interventions,” which highlighted emerging discoveries in the molecular and clinical mechanisms of premature aging and explored novel preventive and therapeutic strategies.activity Frontiers in Aging
2024 - 2026Journal ServiceGuest EditorDetailsTopic: Unraveling the Complexities of Premature Aging: Mechanisms and Interventions.activity BMC Complementary Medicine and Therapies; Diabetology & Metabolic Syndrome; Frontiers in Endocrinology; Cellular Physiology and Biochemistry; Frontiers in Immunology; Frontiers in Pharmacology; Int J Data Mining Bioinformatics; J Diabetes Research; J Obesity; Mol Biol Reports; Oncology Research; Front Cardiovasc Med; PLOS ONE; Scientific Reports; Front Mol Biosci; Front Genetics; Metabolic Brain Disease; Biochem Genetics; Sci World J; J Pharm Innovation; J Clin Med; Diabetology; Nutrients; Healthcare; Diseases; Int J Bioinformatics Res Appl; Biology; Genes; Front Oncology; Int J Mol Sci; Vaccines; Biomedicines; Curr Issues Mol Biol; Front Sports Active Living; Cell Mol Life Sci; Antioxidants; Exp Biol Med; Microorganisms; Front Allergy; Metabolites; Naunyn-Schmiedeberg's Arch Pharmacol; Front Nutrition; Cell Commun Signal.
2022 - 2026Journal ServiceReviewer
News & Links
Copy Link
News
Get In Touch
Copy Link